The Orphan Drug Act (ODA) was first passed in 1983 to address the concern that pharmaceutical manufacturers were not pursuing drug development for diseases that affect limited patient populations. The concern was in part that companies viewed pursuing these therapies as undesirable because the markets for them are small in comparison with the markets for more widespread chronic diseases. To promote the development of orphan drug therapies, the ODA provided companies that engaged in research for drugs with populations of fewer than 200 000 patients with tax incentives, research subsidies, and extended market exclusivity. With the new incentives in place, drug companies began developing more of these drugs. As of August 2018, a total of 503 new orphan therapies had been approved following the passage of the act.1
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Thomas S, Caplan A. The Orphan Drug Act Revisited. JAMA. 2019;321(9):833–834. doi:10.1001/jama.2019.0290
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: